Simplifying Global Compliance
FDA Finalizes Guidance on CMC Submissions for Gene Therapies
Washington Drug Letter
The FDA is detailing its expectations for chemistry, manufacturing and control information that is included in INDs for gene therapies.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing